This trial showed the very favorable tolerability, safety, and pharmacokinetic profile of REL-1017.
Reliance, Relmada’s phase 3 clinical development program for REL-1017, is designed to support FDA approval for the treatment of MDD. Recent data from Reliance completed studies confirm potential efficacy in MDD and a very favorable safety profile with the lack of meaningful risk of abuse. New phase 3 clinical trials in the Reliance program will endeavor to provide the necessary evidence to support a successful FDA submission for REL-1017, a new NMDA inhibitor as an effective and safe alternative to treat MDD. You can learn more at reliancestudies.com.
Scroll to see more
Relmada Therapeutics has obtained development and commercial rights to a novel Neuroplastogen™ program from Arbormentis LLC. Neuroplastogen drugs have the potential to restore impaired neural plasticity. Relmada will collaborate with Arbormentis on the development of new therapies without psychedelic effects targeting neurological and psychiatric disorders, leveraging its understanding of neural plasticity. While psilocybin in high doses is a psychedelic drug that can alter a person’s awareness of their thoughts, feelings, and surroundings, lower doses and improved formulations of psilocybin and its derivatives have the potential for enhancing neural plasticity without causing psychedelic effects.